Access to cervical cancer screening among women living with HIV in Malawi: Analysis of MPHIA 2020–21 and 2015–16 surveys

Gunde L.¹, Payne D.¹, Wang A.¹, Kabaghe A.¹, Maida A.¹, Kayira D.¹, Rabold E.², Jonnalagadda S.², Kumwenda O.³, Phiri T.⁴, Kachingwe J.⁴, Jenda T.⁴, Chiwoko J.⁵, Mangulenje E.⁶, Farahani M.⁷, Kayigamba F.⁸, Mirkovic K.¹, Nyirenda R.⁴, and the MPHIA Study Team 1 CDC Malawi, 2 CDC Atlanta, 3 USAID Malawi, 4 Malawi Ministry of Health, 5 Lighthouse Trust, 6 EGPAF, 7 ICAP New York, 8 ICAP Malawi

BACKGROUND

- Malawi has the highest cervical cancer (CxCa) burden.
- WLHIV are 6 times more likely to develop CxCa.
- Screening and treatment of pre-cancer can help eliminate CxCa.
- Since October 2018, PEPFAR Malawi supports CxCa screening and treatment for WLHIV in high-burden ART facilities.

RESULTS

 1,507 and 1,616 WLHIV were interviewed in 2015-16 and 2020-21, respectively.

Significant improvement in CxCa screening in 5 years

 2.4-fold (p<.0001) between 2015 and 2020 [16.0% (95%) CI: 13.6%-18.7%) compared to 38.4% (95% CI: 35.3%-41.6%)].

METHODS

- MPHIAs are nationally representative household surveys.
- Self-reported CxCa screening history & ART uptake were collected.
- Analyzed by demographic factors and reported 95% CI.
- Risk ratios were computed using Poisson regression.

Greater improvement in CxCa screening coverage among low SES

• Significant increase in screening coverage in WLHIV with no education (RR=3.3), rural residents (RR=3.0), and lowest wealth quintile (RR=6.6).

Cervical cancer screening among women living with HIV has greatly improved; especially for those with

low Socioeconomic Status






Figure 1: Weighted percentages and RR of CxCa screening among WLHIV by SES

Laurence Gunde | nxc7@cdc.gov

This analysis is supported by the US President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) under the terms of cooperative agreements #U2GGH001226 and #U2GGH002173. The findings and conclusions are those of the authors and do not necessarily represent the official position of the funding agencies.





Presented at IAS 2023, the 12th IAS Conference on HIV Science